Menu Close

Trending

Bayer grabs Chinese okay for CKD therapy Kerendia
Novartis eyes earlier use of PD-1 drug in oesophageal cancer
A 3-step guide to addressing difficult issues and creating mutual solutions
AZ takes aim at BMS’ lead in neoadjuvant NSCLC
Blueprint cashes in on the past to build its future

allogeneic

Atara_bio

News/ News/ Oncology

Milestone as EMA starts review of Atara’s ‘off-the-shelf’ cell therapy

, , , , , , 0 Comment

Atara Biotherapeutics’ tabelecleucel (tab-cel) has become the first ‘allogeneic’ cell therapy – in other words one which doesn’t

X
Milestone as EMA starts review of Atara’s ‘off-the-shelf’ cell therapy
https://pharmaphorum.com/news/milestone-as-ema-starts-review-of-ataras-off-the-shelf-cell-therapy/
Heat_Biologics_logo

News/ News/ Oncology

Heat Bio’s shares ignite on Opdivo combination data in NSCLC

, , , , , , , 0 Comment

The pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival

X
Heat Bio’s shares ignite on Opdivo combination data in NSCLC
https://pharmaphorum.com/news/heat-bios-shares-ignite-on-opdivo-combination-data-in-nsclc/

Login

CONTINUE TO SITE >
X
Close in 10 seconds